Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells
- 630 Downloads
The standard of care for treating patients with pancreatic adenocarcinomas includes gemcitabine (2′,2′-difluorodeoxycytidine). Gemcitabine primarily elicits its response by stalling the DNA replication forks of cells in the S phase of the cell cycle. To provide a quantitative framework for characterizing the cell cycle and apoptotic effects of gemcitabine, we developed a pharmacodynamic model in which the activation of cell cycle checkpoints or cell death is dependent on gemcitabine exposure.
Three pancreatic adenocarcinoma cell lines (AsPC-1, BxPC-3, and MiaPaca-2) were exposed to varying concentrations (0–100,000 ng/mL) of gemcitabine over a period of 96 h in order to quantify proliferation kinetics and cell distributions among the cell cycle phases. The model assumes that the drug can inhibit cycle-phase transitioning in each of the 3 phases (G1, S, and G2/M) and can cause apoptosis of cells in G1 and G2/M phases. Fitting was performed using the ADAPT5 program.
The time course of gemcitabine effects was well described by the model, and parameters were estimated with good precision. Model predictions and experimental data show that gemcitabine induces cell cycle arrest in the S phase at low concentrations, whereas higher concentrations induce arrest in all cell cycle phases. Furthermore, apoptotic effects of gemcitabine appear to be minimal and take place at later time points.
The pharmacodynamic model developed provides a quantitative, mechanistic interpretation of gemcitabine efficacy in 3 pancreatic cancer cell lines, and provides useful insights for rational selection of chemotherapeutic agents for combination therapy.
KeywordsModeling Gemcitabine Cell cycle Cytotoxicity Pharmacodynamics
This work is supported by Grant GM57980 from the National Institutes of Health. SSH was supported by a Fellowship from Hoffmann-La Roche Inc.
- 4.Carpenelli G, Bucci G, D’Agnano I, Canese R, Caroli F, Raus L, Brunetti E, Giannarelli E, Podo F, Carapella CM (2006) Gemcitabine treatment of experimental C6 glioma: the effects on cell cycle and apoptotic rate. Anticancer Res 26:3017–3024Google Scholar
- 13.D’Argenio DZ, Schumitzky A, Wang X (2009) ADAPT 5 user’s guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los AngelesGoogle Scholar
- 30.Holcomb B, Yip-Schneider MT, Matos JM, Dixon J, Kennard J, Mahomed J, Shanmugam R, Sebolt-Leopold J, Schmidt CM (2008) Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based targeting strategies. J Gastrointest Surg 12:288–296PubMedCrossRefGoogle Scholar
- 33.Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Shumway SD, Mizuarai S, Hirai H, Maitra A, Hidalgo M (2011) MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regression selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 17:2799–27806PubMedCrossRefGoogle Scholar
- 34.Walton MI, Eve PD, Hayes A, Valenti M, De Haven Brandon A, Box G, Boxall KJ, Aherne GW, Eccles SA, Raynoud FI, Williams DH, Reader JC, Collins I, Garrett MD (2010) The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. Mol Cancer Ther 9:89–100PubMedCrossRefGoogle Scholar
- 35.Xu H, Cheung IY, Wei XX, Tran H, Gao X, Cheung NK (2011) Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G(1) checkpoint-defective neuroblastoma. Int J Cancer 129:153–162Google Scholar
- 39.Tempero M, Plunkett W, van Haperen VR, Hainsworth J, Hochester H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402–3408PubMedCrossRefGoogle Scholar
- 40.Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reicheld S, Howat WJ, Chang A, Dhara M, Wang L, Ruckert F, Grutzmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324:1457–1461PubMedCrossRefGoogle Scholar